BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 25298408)

  • 41. Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex.
    Kovalenko A; Sanin A; Kosmas K; Zhang L; Wang J; Akl EW; Giannikou K; Probst CK; Hougard TR; Rue RW; Krymskaya VP; Asara JM; Lam HC; Kwiatkowski DJ; Henske EP; Filippakis H
    Cancer Res; 2021 Apr; 81(8):2086-2100. PubMed ID: 33593821
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renal disease in tuberous sclerosis complex: pathogenesis and therapy.
    Lam HC; Siroky BJ; Henske EP
    Nat Rev Nephrol; 2018 Nov; 14(11):704-716. PubMed ID: 30232410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.
    Sun Y; Gu X; Zhang E; Park MA; Pereira AM; Wang S; Morrison T; Li C; Blenis J; Gerbaudo VH; Henske EP; Yu JJ
    Cell Death Dis; 2014 May; 5(5):e1231. PubMed ID: 24832603
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis.
    Neuman NA; Henske EP
    EMBO Mol Med; 2011 Apr; 3(4):189-200. PubMed ID: 21412983
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolomic studies identify changes in transmethylation and polyamine metabolism in a brain-specific mouse model of tuberous sclerosis complex.
    McKenna J; Kapfhamer D; Kinchen JM; Wasek B; Dunworth M; Murray-Stewart T; Bottiglieri T; Casero RA; Gambello MJ
    Hum Mol Genet; 2018 Jun; 27(12):2113-2124. PubMed ID: 29635516
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impaired Mitochondrial Dynamics and Mitophagy in Neuronal Models of Tuberous Sclerosis Complex.
    Ebrahimi-Fakhari D; Saffari A; Wahlster L; Di Nardo A; Turner D; Lewis TL; Conrad C; Rothberg JM; Lipton JO; Kölker S; Hoffmann GF; Han MJ; Polleux F; Sahin M
    Cell Rep; 2016 Oct; 17(4):1053-1070. PubMed ID: 27760312
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TSC2 N-terminal lysine acetylation status affects to its stability modulating mTORC1 signaling and autophagy.
    García-Aguilar A; Guillén C; Nellist M; Bartolomé A; Benito M
    Biochim Biophys Acta; 2016 Nov; 1863(11):2658-2667. PubMed ID: 27542907
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.
    Gao Y; Gartenhaus RB; Lapidus RG; Hussain A; Zhang Y; Wang X; Dan HC
    Mol Cancer Res; 2015 Dec; 13(12):1602-14. PubMed ID: 26374334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations.
    Aksoylu IS; Martin P; Robert F; Szkop KJ; Redmond NE; Bhattacharyya S; Wang J; Chen S; Beauchamp RL; Nobeli I; Pelletier J; Larsson O; Ramesh V
    Mol Autism; 2023 Oct; 14(1):39. PubMed ID: 37880800
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
    Yang F; Yang L; Wataya-Kaneda M; Hasegawa J; Yoshimori T; Tanemura A; Tsuruta D; Katayama I
    J Dermatol Sci; 2018 Feb; 89(2):155-164. PubMed ID: 29146131
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis.
    Kang YJ; Lu MK; Guan KL
    Cell Death Differ; 2011 Jan; 18(1):133-44. PubMed ID: 20616807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
    Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
    Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex.
    Lu Y; Zhang EY; Liu J; Yu JJ
    Orphanet J Rare Dis; 2020 Aug; 15(1):209. PubMed ID: 32807195
    [TBL] [Abstract][Full Text] [Related]  

  • 54. mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy.
    Taneike M; Nishida K; Omiya S; Zarrinpashneh E; Misaka T; Kitazume-Taneike R; Austin R; Takaoka M; Yamaguchi O; Gambello MJ; Shah AM; Otsu K
    PLoS One; 2016; 11(3):e0152628. PubMed ID: 27023784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.
    Ogórek B; Lam HC; Khabibullin D; Liu HJ; Nijmeh J; Triboulet R; Kwiatkowski DJ; Gregory RI; Henske EP
    Hum Mol Genet; 2018 May; 27(9):1654-1663. PubMed ID: 29509898
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fetal brain mTOR signaling activation in tuberous sclerosis complex.
    Tsai V; Parker WE; Orlova KA; Baybis M; Chi AW; Berg BD; Birnbaum JF; Estevez J; Okochi K; Sarnat HB; Flores-Sarnat L; Aronica E; Crino PB
    Cereb Cortex; 2014 Feb; 24(2):315-27. PubMed ID: 23081885
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.
    Alves MM; Fuhler GM; Queiroz KC; Scholma J; Goorden S; Anink J; Spek CA; Hoogeveen-Westerveld M; Bruno MJ; Nellist M; Elgersma Y; Aronica E; Peppelenbosch MP
    Sci Rep; 2015 Sep; 5():14534. PubMed ID: 26412398
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Distinct germline progenitor subsets defined through Tsc2-mTORC1 signaling.
    Hobbs RM; La HM; Mäkelä JA; Kobayashi T; Noda T; Pandolfi PP
    EMBO Rep; 2015 Apr; 16(4):467-80. PubMed ID: 25700280
    [TBL] [Abstract][Full Text] [Related]  

  • 59. mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex.
    Pema M; Drusian L; Chiaravalli M; Castelli M; Yao Q; Ricciardi S; Somlo S; Qian F; Biffo S; Boletta A
    Nat Commun; 2016 Mar; 7():10786. PubMed ID: 26931735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Finding a cure for tuberous sclerosis complex: From genetics through to targeted drug therapies.
    McEneaney LJ; Tee AR
    Adv Genet; 2019; 103():91-118. PubMed ID: 30904097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.